Concepedia

Philip R. Hamann

PR

Statistics

Publications

27

Citations

2.8K

H-Index

23

Active since

1983

Affiliations

Pearl River Community College(Current)

Fred Hutch Cancer Center

Women's Health Research Institute

Columbia University

Pfizer (United States)

Philip R. Hamann is an author at Pearl River Community College specializing in chemotherapy, antibody-drug conjugates, and medicinal chemistry.

Publications per year

1983–2011

27

Publications

27

Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia

Philip R. Hamann, Lois M. Hinman, Irwin Hollander et al. · Bioconjugate Chemistry · 2001 · 587 citations

, , +17

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

John F. DiJoseph, Douglas Armellino, Erwin R. Boghaert et al. · Blood · 2003 · 356 citations · Full text

, , +11

Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

Lois M. Hinman, Philip R. Hamann, Ryan M. Wallace et al. · PubMed · 1993 · 238 citations

, , +17

An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker

Philip R. Hamann, Lois M. Hinman, Carl F. Beyer et al. · Bioconjugate Chemistry · 2001 · 227 citations

, , +17

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma

John F. DiJoseph, Maureen Dougher, Lyka B. Kalyandrug et al. · Clinical Cancer Research · 2006 · 140 citations · Full text

, , +17

1–5 of 27